Prostate cancer induces bone metastasis through Wnt-induced bone morphogenetic protein-dependent and independent mechanisms

Cancer Research

Volumn 68, Issue 14, 2008, Pages 5785-5794

  Dai, Jinlu ^a   Hall, Christopher L ^a   Escara Wilke, June ^a   Mizokami, Atsushi ^b   Keller, Jill M ^a   Keller, Evan T ^a,c  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXIN; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 4; DKK 1; NOGGIN; PROTEIN INHIBITOR; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; UNCLASSIFIED DRUG; WNT PROTEIN; WNT3A PROTEIN; WNT5A PROTEIN; BONE MORPHOGENETIC PROTEIN 6; DKK1 PROTEIN, HUMAN; ONCOPROTEIN; SIGNAL PEPTIDE; WNT3 PROTEIN; WNT5A PROTEIN, HUMAN;

ARTICLE; BONE METASTASIS; CELL DIFFERENTIATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OSTEOBLAST; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; CELL STRAIN 3T3; GENE EXPRESSION REGULATION; MALE; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; PROSTATE TUMOR; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; BONE MORPHOGENETIC PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICE; NEOPLASM METASTASIS; OSTEOBLASTS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; WNT PROTEINS;

EID: 48649090754     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6541     Document Type: Article

References (58)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. Bubendorf L, Schopfer A, Wagner U, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
3. Keller ET, Brown J. Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 2004;91:718-29.
4. Keller ET. The role of osteoclastic activity in prostate cancer skeletal metastases. Drugs Today Barc 2002;38:91-102.
5. Reddi AH, Roodman D, Freeman C, Mohla S. Mechanisms of tumor metastasis to the bone: challenges and opportunities. J Bone Miner Res 2003;18:190-4.
6. Dai J, Keller J, Zhang J, Lu Y, Yao Z, Keller ET. Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. Cancer Res 2005;65:8274-85.
7. Nelson JB, Nguyen SH, Wu-Wong JR, et al. New bone formation in an osteoblastic tumor model is increased by endothelin-1 overexpression and decreased by endothelin A receptor blockade. Urology 1999;53:1063-9.
8. Dai J, Kitagawa Y, Zhang J, et al. Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res 2004;64:994-9.
9. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005;65:7554-60.
10. Reddi AH. Bone morphogenetic proteins: an unconventional approach to isolation of first mammalian morphogens. Cytokine Growth Factor Reviews 1997;8:11-20.
11. Wan M, Shi X, Feng X, Cao X. Transcriptional Mechanisms of BMP-Induced Osteoprotegrin Gene Expression. J Biol Chem 2001;276:10119-25. Epub 2001 Jan 3.
12. Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL. Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation. J Bone Miner Res 1999;14:1522-35.
13. Li IW, Cheifetz S, McCulloch CA, Sampath KT, Sodek J. Effects of osteogenic protein-1 (OP-1, BMP-7) on bone matrix protein expression by fetal rat calvarial cells are differentiation stage specific. J Cell Physiol 1996;169:115-25.
14. Maliakal JC, Asahina I, Hauschka PV, Sampath TK. Osteogenic protein-1 (BMP-7) inhibits cell proliferation and stimulates the expression of markers characteristic of osteoblast phenotype in rat osteosarcoma (17/2.8) cells. Growth Factors 1994;11:227-34.
15. Harris SE, Harris MA, Mahy P, Wozney J, Feng JQ, Mundy GR. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 1994;24:204-11.
16. Barnes J, Anthony CT, Wall N, Steiner MS. Bone morphogenetic protein-6 expression in normal and malignant prostate. World J Urol 1995;13:337-43.
17. Hamdy FC, Autzen P, Robinson MC, Horne CH, Neal DE, Robson CN. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue. Cancer Res 1997;57:4427-31.
18. Doak SH, J enkins SA, Hurle RA, et al. Bone morphogenic factor gene dosage abnormalities in prostatic intraepithelial neoplasia and prostate cancer. Cancer Genet Cytogenet 2007;176:161-5.
19. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007;171:1047-57.
20. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;281:22429-33.
21. Westendorf JJ, Kahler RA, Schroeder TM. Wnt signaling in osteoblasts and bone diseases. Gene 2004;341:19-39.
22. Barrow JR, Thomas KR, Boussadia-Zahui O, et al. Ectodermal Wnt3/β-catenin signaling is required for the establishment and maintenance of the apical ectodermal ridge. Genes Dev 2003;17:394-409.
23. Nakashima A, Katagiri T, Tamura M. Cross-talk between Wnt and bone morphogenetic protein 2 (BMP-2) signaling in differentiation pathway of C2C12 myoblasts. J Biol Chem 2005;280:37660-8.
24. Bonny C, Oberson A, Negri S, Sauser C, Schorderet DF. Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes 2001;50:77-82.
25. Thalmann GN, Anezinis PE, Chang SM, et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994;54:2577-81.
26. Corey E, Quinn JE, Bladou F, et al. Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells. Prostate 2002;52:20-33.
27. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S. Wnt proteins prevent apoptosis of both uncommitted osteoblast progenitors and differentiated osteoblasts by β-catenin-dependent and -independent signaling cascades involving Src/ERK and phosphatidylinositol 3-kinase/AKT. JBiol Chem 2005;280:41342-51.
28. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits β-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:e115.
29. Helvering LM, Sharp RL, Ou X, Geiser AG. Regulation of the promoters for the human bone morphogenetic protein 2 and 4 genes. Gene 2000;256:123-38.
30. Tamada H, Kitazawa R, Gohji K, Kamidono S, Maeda S, Kitazawa S. Molecular cloning and analysis of the 5′-flanking region of the human bone morphogenetic protein-6 (BMP-6). Biochim Biophys Acta 1998;1395:247-51.
31. Hall CL, Kang S, MacDougald OA, Keller ET. Role of Wnts in prostate cancer bone metastases. J Cell Biochem 2006;97:661-72.
32. Canalis E, Economides AN, Gazzerro E. Bone morphogenetic proteins, their antagonists, and the skeleton. Endocrine reviews 2003;24:218-35.
33. Gazzerro E, Canalis E. Bone morphogenetic proteins and their antagonists. Rev Endocr Metab Disord 2006;7:51-65.
34. Rosen V. BMP and BMP inhibitors in bone. Ann N Y Acad Sci 2006;1068:19-25.
35. Yanagita M. BMP antagonists: their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 2005;16:309-17.
36. Weber KL, Bolander ME, Rock MG, Pritchard D, Sarkar G. Evidence for the upregulation of osteogenic protein-1 mRNA expression in musculoskeletal neoplasms. J Orthop Res 1998;16:8-14.
37. Bentley H, Hamdy FC, Hart KA, et al. Expression of bone morphogenetic proteins in human prostatic adenocarcinoma and benign prostatic hyperplasia. Br J Cancer 1992;66:1159-63.
38. Hughes FJ, Collyer J, Stanfield M, Goodman SA. The effects of bone morphogenetic protein-2, -4, and -6 on differentiation of rat osteoblast cells in vitro. Endocrinology 1995;136:2671-7.
39. Thomas R, Anderson WA, Raman V, Reddi AH. Androgen-dependent gene expression of bone morphogenetic protein 7 in mouse prostate. Prostate 1998;37:236-45.
40. Itaranta P, Chi L, Seppanen T, et al. Wnt-4 signaling is involved in the control of smooth muscle cell fate via Bmp-4 in the medullary stroma of the developing kidney. Dev Biol 2006;293:473-83.
41. Haegele L, Ingold B, Naumann H, Tabatabai G, Ledermann B, Brandner S. Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Mol Cell Neurosci 2003;24:696-708.
42. Kim JS, Crooks H, Dracheva T, et al. Oncogenic β-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002;62:2744-8.
43. Godin RE, Takaesu NT, Robertson EJ, Dudley AT. Regulation of BMP7 expression during kidney development. Development 1998;125:3473-82.
44. Rawadi G, Vayssiere B, Dunn F, Baron R, Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 2003;18:1842-53.
45. Ozkaynak E, Jin DF, Jelic M, Vukicevic S, Oppermann H. Osteogenic protein-1 mRNA in the uterine endometrium. Biochem Biophys Res Commun 1997;234:242-6.
46. Faucheux C, Bareille R, Amedee J, Triffitt JT. Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression. JC ell Biochem 1999;73:11-9.
47. Grimsrud CD, Rosier RN, Puzas JE, et al. Bone morphogenetic protein-7 in growth-plate chondrocytes: regulation by retinoic acid is dependent on the stage of chondrocyte maturation. JOrthop Res 1998;16:247-55.
48. Feng JQ, Chen D, Cooney AJ, et al. The mouse bone morphogenetic protein-4 gene. Analysis of promoter utilization in fetal rat calvarial osteoblasts and regulation by COUP- TFI orphan receptor. J Biol Chem 1995;270:28364-73.
49. Kawai S, Sugiura T. Characterization of human bone morphogenetic protein (BMP)-4 and -7 gene promoters: activation of BMP promoters by Gli, a sonic hedgehog mediator. Bone 2001;29:54-61.
50. Paralkar VM, Grasser WA, Mansolf AL, et al. Regulation of BMP-7 expression by retinoic acid and prostaglandin E(2). JC ell Physiol 2002;190:207-17.
51. Feng JQ, Harris MA, Ghosh-Choudhury N, Feng M, Mundy GR, Harris SE. Structure and sequence of mouse bone morphogenetic protein-2 gene (BMP- 2): comparison of the structures and promoter regions of BMP-2 and BMP- 4 genes. Biochim Biophys Acta 1994;1218:221-4.
52. Mohammad KS, Guise TA. Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop 2003:S67-74.
53. Tenta R, Tiblalexi D, Sotiriou E, Lembessis P, Manoussakis M, Koutsilieris M. Bone microenvironment-related growth factors modulate differentially the anticancer actions of zoledronic acid and doxorubicin on PC-3 prostate cancer cells. Prostate 2004;59:120-31.
54. Mbalaviele G, Sheikh S, Stains JP, et al. β-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem 2005;94:403-18.
55. Yang L, Yamasaki K, Shirakata Y, et al. Bone morphogenetic protein-2 modulates Wnt and frizzled expression and enhances the canonical pathway of Wnt signaling in normal keratinocytes. J Dermatol Sci 2006;42:111-9.
56. Winkler DG, Sutherland MS, Ojala E, et al. Sclerostin inhibition of Wnt-3a-induced C3H10T1/2 cell differentiation is indirect and mediated by bone morphogenetic proteins. JBiol Chem 2005;280:2498-502.
57. Chen Y, Whetstone HC, Youn A, et al. h-catenin signaling pathway is crucial for bone morphogenetic protein 2 to induce new bone formation. J Biol Chem 2007;282:526-33.
58. van Bezooijen RL, Svensson JP, Eefting D, et al. Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 2007;22:19-28.